Abstract
Kinesin spindle protein (KSP), a mitotic kinesin responsible for bipolar spindle establishment and maintenance, is currently the target of intense research for the development of novel anticancer therapeutics. Several inhibitors of KSP have progressed into clinical trials and many others are in preclinical development. A majority of these inhibitors are ATP-uncompetitive and bind in an allosteric loop L5 binding pocket, but recently, inhibitors with an alternative mechanism of action (ATP-competitive) have also been identified and characterized. In this review, an update of the clinical trial results with ATP-uncompetitive KSP inhibitors is provided and recent progress in the identification of additional KSP inhibitors is discussed.
Keywords: Kinesin, inhibitor, kinesin spindle protein, KSP, Eg5, cancer
Current Topics in Medicinal Chemistry
Title: Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP
Volume: 8 Issue: 10
Author(s): Steven D. Knight and Cynthia A. Parrish
Affiliation:
Keywords: Kinesin, inhibitor, kinesin spindle protein, KSP, Eg5, cancer
Abstract: Kinesin spindle protein (KSP), a mitotic kinesin responsible for bipolar spindle establishment and maintenance, is currently the target of intense research for the development of novel anticancer therapeutics. Several inhibitors of KSP have progressed into clinical trials and many others are in preclinical development. A majority of these inhibitors are ATP-uncompetitive and bind in an allosteric loop L5 binding pocket, but recently, inhibitors with an alternative mechanism of action (ATP-competitive) have also been identified and characterized. In this review, an update of the clinical trial results with ATP-uncompetitive KSP inhibitors is provided and recent progress in the identification of additional KSP inhibitors is discussed.
Export Options
About this article
Cite this article as:
Knight D. Steven and Parrish A. Cynthia, Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP, Current Topics in Medicinal Chemistry 2008; 8 (10) . https://dx.doi.org/10.2174/156802608784911626
DOI https://dx.doi.org/10.2174/156802608784911626 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Curcumin Treated Non-Small Cell Lung Cancers: An Impetus of Pleiotropic Traits and Nanocarrier Aided Delivery
Current Medicinal Chemistry Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery ExomiRs: A Novel Strategy in Cancer Diagnosis and Therapy
Current Gene Therapy Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Targeting the Epidermal Growth Factor Receptor Family in Radionuclide Therapy of Tumors – Signal Transduction and DNA Repair
Letters in Drug Design & Discovery The Role of Biomarker Genes in the Diagnosis and Treatment of Nonsmall Cell Lung Cancer
Current Respiratory Medicine Reviews Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Editorial (Thematic Issue: Targeted Anti-Cancer Drug Delivery)
Current Cancer Drug Targets Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Role of α6β4 Integrin in Cell Motility, Invasion and Metastasis of Mammary Tumors
Current Protein & Peptide Science Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism